Trial Profile
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Bicalutamide; Flutamide; Nilutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ANZUP ENZARAD; ENZARAD
- 15 Dec 2022 Planned End Date changed from 1 Jul 2024 to 1 Dec 2025.
- 15 Dec 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Apr 2021 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.